Is Revolution Medicines Inc (RVMD) a risky stock?
As of July 21, 2026, Clavix grades Revolution Medicines Inc (RVMD) B- for risk, a composite score of 67 out of 100 on an A+ to F scale, which puts RVMD in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind RVMD's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how RVMD scores on each, as of July 21, 2026.
What's moving RVMD's risk right now
Company-specific signals Clavix flags behind RVMD's current grade, drawn from recent news and filings as of July 21, 2026.
For RVMD specifically, the stock's 135% year-to-date surge and positive phase 3 oncology results position it as a high-trend name, though the article's full comparative verdict…
The phased rating update and orphan designation signal meaningful European regulatory trend for daraxonrasib, potentially shortening its path to EU approval in pancreatic cancer and s…
Margin trajectory is stable but offers no near-term catalyst to drive meaningful earnings upside.
What a B- grade means
On the Clavix A+ to F scale, RVMD's composite of 67 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell RVMD or any security. Grades are risk indicators, not predictions of return. Data may be delayed.